ロード中...

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

Alemtuzumab is a humanized monoclonal antibody against CD52 (cluster of differentiation 52) and is approved for the therapy of relapsing-remitting multiple sclerosis. The application of alemtuzumab leads to a rapid, but long-lasting depletion predominantly of CD52-bearing B and T cells with reprogra...

詳細記述

保存先:
書誌詳細
出版年:Int J Mol Sci
主要な著者: Ruck, Tobias, Bittner, Stefan, Wiendl, Heinz, Meuth, Sven G.
フォーマット: Artigo
言語:Inglês
出版事項: MDPI 2015
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4519957/
https://ncbi.nlm.nih.gov/pubmed/26204829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms160716414
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!